Latest News and Press Releases
Want to stay updated on the latest news?
-
VALNEVA Déclaration d’actions et de droits de vote 30 septembre 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse...
-
VALNEVA Declaration of shares and voting rights September 30, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6...
-
New York, USA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight According to DelveInsight’s analysis,...
-
Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultesLa durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant...
-
Long-lasting antibody persistence was comparable in older (65+) and younger adultsLong-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases...
-
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to...
-
Valneva ADRs plunged after CDC probed IXCHIQ safety in Feb. 2025, then fell further in Aug. 2025 when FDA suspended the vaccine’s application.
-
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to...
-
CDC, then FDA flagged safety issues with IXCHIQ; Valneva ADRs fell 13.6% in Feb. and another 19% in Aug. 2025 on suspension news.
-
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to...